查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1834182

2025-2032 年全球人工 T 细胞市场预测（按治疗类型、细胞来源、阶段、应用和最终用户划分）

Engineered T Cells Market by Therapy Type, Cell Source, Phase, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，人工 T 细胞市场将成长至 224.2 亿美元，复合年增长率为 26.44%。

主要市场统计数据
基准年2024年 34.3亿美元
预计2025年 43.4亿美元
预测年份：2032年 224.2亿美元
复合年增长率（%） 26.44%

工程化T细胞的策略部署，专注于科学进步、有前景的治疗方法、监管演变和相关人员的优先事项

在基因工程、细胞製造和转化科学的推动下，工程化T细胞疗法已从实验室的好奇心发展成为现代免疫疗法的变革性支柱。平台工程和概念验证研究的最新进展使得标靶性更强、耐久性更高、安全管理更精细。这些改进加速了候选疗法从临床前模型到早期和晚期临床评估的进展，拓宽了开发者的治疗愿景，使其从骨髓恶性肿瘤扩展到自体自体免疫感染疾病。

随着科学研究能力的成熟，相关人员的优先事项也随之转变。研发人员必须协调复杂的生物学特性与可扩展的生产和监管预期，而支付方和医疗保健提供者也日益要求获得持续效用和可预测安全性的证据。投资者和策略伙伴正在寻求明确TCR特异性和CAR模组化等差异化特征，以及自体和异体培养之间的细胞来源决策。在此背景下，将实验室创新与可操作的临床路径和供应链韧性相结合的组织策略将决定哪些专案能够推进，哪些专案会停滞不前，这使得现在成为科研领导力和实际执行的关键时刻。

描绘重塑工程化 T 细胞开发、商业性途径、突破性模式和协作生态系统的变革性转变

工程化T细胞领域正在经历几场相互关联的变革，这些变革正在重新定义开发模式和商业性途径。基因编辑、载体设计和细胞製造的技术进步，正在赋能下一代CAR-T和TCR方法，使其特异性更高、脱靶效应更低，并具备模组化安全开关。同时，我们也看到了从单一场所的学术製造向整合但去中心化的製造网络的明显转变，该网络将集中式品管与局部能力相结合，以应对个性化和现成疗法的运作现实。

临床策略也在改变。开发商越来越多地在设计试验时，将生物标记驱动的患者选择和适应症终点纳入考量，同时保持严格的监管要求。生物技术公司、大型製药企业、合约研究公司和临床网路之间的合作模式正在迅速扩展，这得益于将发现的灵活性与后期开发和商业化的优势相结合的需求。同时，报销讨论正推进到研发早期阶段，要求申办方在製定临床方案的同时，制定产生健康经济证据的计画。这些转变正在改变投资标准、合作结构和竞争格局，有利于那些能够同时推动生物创新和营运执行的组织。

评估 2025 年美国关税将如何重塑人工 T 细胞供应链、采购、製造和国际合作

美国关税将于2025年生效，这将为工程化T细胞计画的全球供应和营运计算带来新的变数。关税波动可能会增加病毒载体、一次性耗材和专用试剂等关键投入的到岸成本。依赖跨境原料或契约製造的申办者将需要重新评估供应商的多元化、缓衝库存和合约条款，以维持专案时间表和临床的连续性。

在实践中，关税环境凸显了短期供应链可视性和紧急时应对计画的重要性。区域组织可能更倾向于在受影响地区采购低成本组件与更靠近临床站点的替代供应商提供的灵活性和弹性之间进行权衡。战略应对措施包括重新谈判供应商合约以分配关税风险、在关税稳定的地区确定合格的二级供应商，以及促进替代製造合作伙伴的技术转移。监管提交和临床时间表可能需要进行调整以反映这些营运变化，商业发布计划应纳入对成本结构和分销变化的影响。整体而言，关税变化凸显了采购、製造、监管事务和商业团队之间进行综合规划的必要性，以维持专案发展动能。

细分主导的洞察揭示了治疗方法类型、细胞来源、开发阶段、临床应用和最终用户将如何影响研发重点和策略

细分领域提供了一个视角，可以最有效地评估该领域的策略、临床设计和投资决策。根据治疗类型，计画分为CAR-T和TCR-T两种方法，每种方法都有不同的标靶框架、製造需求和转化风险概况，这些因素会影响适应症重点和合作伙伴的利益。根据细胞来源，同种异体和自体疗法之间的权衡会影响治疗时间、扩充性、免疫抗原性风险和供应链复杂性，进而影响製造设计和商业化模式。根据阶段，开发状态从临床前到I期、II期和III期，每个阶段都有各自的证据要求、製造规模需求和监管互动，这些都会影响资源分配和批准/不批准时间。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 利用基因编辑降低移植物抗宿主风险的现成同种异体 CAR-T 疗法的进展
  • 发展装甲 CAR-T 细胞，分泌细胞激素以增强对固态肿瘤微环境的渗透
  • 透过 CRISPR 介导的多基因编辑提高 T 细胞持久性和安全性
  • 整合自动化、封闭式系统製造平台，扩大 CAR-T 生产规模并降低成本
  • 工程化T细胞与免疫查核点抑制剂的组合策略，以达到协同抗肿瘤反应
  • 针对双抗原的双特异性 CAR-T 构建体的出现，可防止治疗抗药性癌症中的肿瘤抗原逃脱
  • 不断发展的基因改造T细胞疗法监管途径，重点在于统一的全球核准流程
  • 利用人工智慧演算法设计个人化新抗原靶向T细胞受体
  • 推出诱导性多功能干细胞衍生的 CAR-T 产品，旨在标准化细胞治疗供应链
  • 利用分子成像实现即时体内 CAR-T 细胞追踪，以监测安全性和有效性
  • 市场进入倡议重点关注 CAR-T 疗法的创新报销模式和基于绩效的合同

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 人工T细胞市场（依治疗类型）

  • CAR T
  • TCR T

第九章：人工T细胞市场的细胞来源

  • 同种异体
  • 自体移植

第 10 章：人工 T 细胞市场（依阶段）

  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 临床前

第 11 章 人工 T 细胞市场：依应用

  • 自体免疫疾病
    • 狼疮
    • 类风湿性关节炎
  • 感染疾病
  • 肿瘤学
    • 急性淋巴性白血病
    • 非何杰金氏淋巴瘤
    • 固态肿瘤
      • 神经胶母细胞瘤
      • 肺癌

第 12 章 人工 T 细胞市场（依最终用户划分）

  • 医院
  • 研究机构
  • 专科诊所

第十三章 人工T细胞市场：依地区

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 14 章 人工 T 细胞市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国人工T细胞市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Novartis AG
    • Gilead Sciences, Inc.
    • Bristol-Myers Squibb Company
    • Johnson & Johnson
    • Legend Biotech Corporation
    • Allogene Therapeutics, Inc.
    • Adaptimmune Therapeutics plc
    • Poseida Therapeutics, Inc.
    • Celyad Oncology SA
    • Sangamo Therapeutics, Inc.
Product Code: MRR-4348D129FAA9

The Engineered T Cells Market is projected to grow by USD 22.42 billion at a CAGR of 26.44% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.43 billion
Estimated Year [2025] USD 4.34 billion
Forecast Year [2032] USD 22.42 billion
CAGR (%) 26.44%

Strategic introduction to engineered T cells emphasizing scientific advances, therapeutic promise, regulatory evolution, and stakeholder priorities

Engineered T cell therapeutics have evolved from a laboratory curiosity into a transformative pillar of modern immunotherapy, driven by advances in genetic engineering, cell manufacturing, and translational science. Recent years have seen progress not only in proof-of-concept studies but also in platform engineering, enabling more precise targeting, improved persistence, and refined safety controls. These improvements have accelerated the movement of candidate therapies from preclinical models into early and later-stage clinical evaluation, and they have broadened the therapeutic ambitions of developers beyond hematologic malignancies to autoimmune and infectious disease applications.

As scientific capabilities mature, stakeholder priorities are shifting in response. Developers must reconcile complex biology with scalable manufacturing and regulatory expectations, while payers and providers increasingly demand evidence of durable benefit and predictable safety. Investors and strategic partners are looking for clarity around differentiating features such as TCR specificity versus CAR modularity, and around cell source decisions between autologous and allogeneic approaches. Against this backdrop, organizational strategies that connect lab innovation to pragmatic clinical pathways and supply chain resilience will determine which programs advance and which stall, making this a pivotal moment for both scientific leadership and pragmatic execution.

Mapping transformative shifts reshaping engineered T cell development, commercial pathways, breakthrough modalities, and collaborative ecosystems

The engineered T cell field is undergoing several interconnected shifts that are redefining development paradigms and commercial pathways. Technological advances in gene editing, vector design, and cell manufacturing are enabling next-generation CAR and TCR approaches with improved specificity, reduced off-target activity, and modular safety switches. At the same time, there is a clear move from single-site academic manufacturing toward integrated yet distributed production networks that blend centralized quality control with local capacity, responding to the operational realities of personalized and off-the-shelf therapies.

Clinical strategy is also changing: developers are increasingly designing trials that embed biomarker-driven patient selection and adaptive endpoints to accelerate readouts while preserving regulatory rigor. Collaborative models between biotechs, large pharma, contract developers, and clinical networks are proliferating, driven by the need to combine discovery agility with late-stage development and commercialization muscle. Meanwhile, reimbursement conversations are moving earlier in development, prompting sponsors to design health economic evidence generation plans alongside clinical protocols. These shifts are reshaping investment criteria, partnership structures, and the competitive landscape, favoring organizations that can simultaneously innovate biologically and execute operationally.

Assessment of how United States 2025 tariffs could reshape engineered T cell supply chains, component sourcing, manufacturing and international collaboration

United States tariff measures implemented in 2025 introduce new variables into the global supply and operational calculus for engineered T cell programs. Changes in tariff exposure can increase the landed cost of critical inputs such as viral vectors, single-use consumables, and specialized reagents, which in turn pressures manufacturing economics and decisions about where to site production capacity. Sponsors that rely on cross-border flows for raw materials or contract manufacturing will need to reassess supplier diversification, buffer inventories, and contractual terms to preserve program timelines and clinical continuity.

In practice, the tariff environment amplifies the importance of near-term supply chain visibility and contingency planning. Organizations will increasingly evaluate the tradeoffs between sourcing lower-cost components from affected geographies versus the flexibility and resiliency provided by alternative suppliers closer to clinical sites. Strategic responses include renegotiating supplier agreements to allocate tariff risk, qualifying secondary suppliers in tariff-stable jurisdictions, and accelerating technology transfer to alternate manufacturing partners. Regulatory filings and clinical timelines may require adjustment to reflect these operational changes, and commercial launch planning must incorporate revised cost structures and distribution implications. Overall, tariff shifts highlight the need for integrated planning across procurement, manufacturing, regulatory affairs, and commercial teams to maintain program momentum.

Segment-driven insights revealing how therapy types, cell sources, development phases, clinical applications, and end users shape R&D focus and strategy

Segmentation provides the lens through which strategy, clinical design, and investment decisions are most meaningfully assessed in this domain. Based on Therapy Type, programs divide between CAR T and TCR T approaches, each with distinct targeting frameworks, manufacturing requirements, and translational risk profiles, which influence indication focus and partnering interest. Based on Cell Source, decisions between Allogeneic and Autologous approaches determine tradeoffs among time to treatment, scalability, immunogenicity risk, and supply chain complexity, and they inform manufacturing design and commercialization models. Based on Phase, development status ranges from Preclinical to Phase I, Phase II, and Phase III, with each stage presenting unique evidence requirements, manufacturing scale demands, and regulatory interactions that shape resource allocation and go/no-go timing.

Based on Application, therapeutic ambitions extend across Oncology, Infectious Diseases, and Autoimmune Diseases. The Oncology category includes hematologic indications such as Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma, as well as Solid Tumor programs targeting Glioblastoma and Lung Cancer, each presenting different tumor microenvironment challenges and delivery considerations. The Autoimmune Diseases segment further explores indications such as Lupus and Rheumatoid Arthritis, where long-term immune modulation and safety profiles require distinct trial designs. Based on End User, deployment contexts span Hospitals, Research Institutes, and Specialty Clinics, and these end users dictate logistics, in-hospital treatment pathways, and post-treatment monitoring frameworks. Together, these segmentation dimensions reveal where scientific opportunity aligns with operational capability and commercial access potential.

Regional dynamics across the Americas, EMEA, and Asia-Pacific that shape clinical trial activity, strategic partnerships, and patient access approaches

Regional dynamics materially influence development strategy, trial design, and access planning for engineered T cell programs. In the Americas, a dense ecosystem of clinical trial sites, academic centers, and specialized hospitals supports rapid patient accrual for hematologic and select solid tumor protocols, while regulatory pathways emphasize rigorous safety and efficacy evidence. Sponsors intending to launch in these markets must consider payer engagement earlier, as reimbursement expectations and hospital adoption patterns will shape commercial viability and pricing strategy. Cross-border collaborations with manufacturing and distribution partners are common, and logistical coordination across North and South American jurisdictions requires careful planning.

In EMEA, regulatory harmonization and clinical networks offer advantages for multicenter studies, but variations in national reimbursement and health technology assessment processes require tailored value demonstration strategies. Capacity constraints at transplantation and specialized cell therapy centers can influence site selection and operational timelines. In Asia-Pacific, there is a growing clinical and manufacturing footprint with strong public and private investment in advanced therapies, and adaptive regulatory initiatives in several markets can expedite local development and market entry. However, regional intellectual property considerations, local partnering norms, and differing healthcare delivery models require sponsors to adapt clinical, regulatory, and commercialization approaches to each submarket. Understanding these regional nuances is essential to align clinical development, manufacturing footprints, and market access plans.

Profiles of leading companies highlighting R&D platforms, manufacturing capabilities, partnership models, clinical pipelines, and commercialization priorities

Company-level dynamics are central to competitive positioning and partnership opportunities across the engineered T cell landscape. Leading developers are differentiating by technological platform-whether in CAR architecture, TCR discovery engines, gene editing methods, or safety switch implementations-and by the depth of their proprietary manufacturing know-how and scale capabilities. Strategic partnerships frequently pair early-stage innovators that hold unique targeting biology with larger organizations that provide late-stage development capacity, regulatory experience, and commercial infrastructure. Contract development and manufacturing organizations also play a pivotal role, offering modular solutions to reduce time to clinic and to support geographic expansion.

Investors and potential partners evaluate companies on a combination of scientific differentiation, clinical evidence progression across phases, supply chain robustness, and the clarity of commercialization pathways for target indications. Companies that articulate a compelling translational rationale, backed by reproducible manufacturing processes and an evidence generation plan addressing both clinical outcomes and health economic endpoints, are most likely to secure strategic collaborations and downstream commercial opportunities. Operational execution-ranging from vector supply to site training and long-term follow-up mechanisms-remains a critical determinant of whether scientific promise converts into sustainable therapeutic programs.

Practical recommendations for leaders to speed translation, optimize supply chains, forge strategic partnerships, and align regulatory/reimbursement approaches

Industry leaders should take immediate, prioritized actions to bridge scientific innovation with operational and commercial readiness. First, align clinical development plans with evidence needs of regulators and payers by integrating biomarker strategies, long-term follow-up protocols, and health economic endpoints into trial designs early. This alignment reduces the risk of later-stage surprises and strengthens value conversations at launch. Second, build supply chain resilience by qualifying secondary suppliers, exploring regional manufacturing hubs, and negotiating supplier contracts that include tariff and logistics contingencies. These measures reduce exposure to external shocks and support reliable clinical supply.

Third, pursue partnership models that complement internal capabilities: consider risk-sharing and co-development structures with partners that bring regulatory and commercialization scale, while preserving optionality for lead asset development. Fourth, invest in manufacturing transferability and quality systems that enable reproducible processes across sites, thereby reducing time to clinic and supporting broader geographic rollout. Finally, create cross-functional governance that connects R&D, manufacturing, regulatory affairs, and commercial teams to ensure coordinated decision-making on clinical prioritization, evidence generation, and market access strategies. These steps will enable organizations to convert program potential into measurable clinical and commercial outcomes.

Transparent research methodology outlining data sources, expert engagements, analytical frameworks, validation steps, and study limitations for decision-making

The research approach underpinning these insights combined a multi-method framework to ensure analytical rigor and practical relevance. Primary inputs included structured interviews with subject matter experts spanning clinical investigators, manufacturing leads, regulatory advisors, and commercial strategists to capture real-world operational constraints and strategic considerations. Secondary research reviewed peer-reviewed literature, publicly available regulatory guidance, company disclosures, and clinical trial registries to contextualize pipeline activity and therapeutic approaches. Analytical frameworks incorporated segmentation by therapy type, cell source, development phase, application, and end user to map where scientific innovation intersects with operational demand.

Validation steps included cross-checking expert statements against publicly disclosed trial and regulatory milestones, and synthesizing patterns across multiple data sources to mitigate single-source bias. Study limitations are acknowledged: proprietary commercial agreements and confidential development programs may not be fully reflected, and emerging technologies can evolve rapidly, which necessitates ongoing monitoring. Nevertheless, the combination of expert engagement, evidence triangulation, and structured analytical lenses provides a robust foundation for strategic planning and decision-making.

Concluding synthesis of strategic imperatives, scientific pathways, operations, and collaborative models shaping the future of engineered T cell therapeutics

The cumulative analysis highlights a clear imperative: converting engineered T cell promise into durable clinical and commercial impact requires simultaneous excellence in biology, manufacturing, and market execution. Scientific advances in CAR and TCR engineering offer pathways to expanded indications and improved therapeutic windows, but technical novelty alone is insufficient without scalable, quality-assured manufacturing and compelling evidence that addresses payer and provider expectations. Operational realities-from cell sourcing choices between autologous and allogeneic options to the phase-specific demands of clinical development-must be anticipated and integrated into program planning to avoid costly delays.

Collaborative models that pair nimble scientific organizations with partners that offer development scale and access capabilities will continue to dominate successful pathways to market. Regionally informed strategies are essential, as regulatory, clinical capacity, and reimbursement conditions vary across the Americas, EMEA, and Asia-Pacific. By aligning translational science with pragmatic operational planning and early payer engagement, stakeholders can increase the probability that engineered T cell innovations reach patients and sustain commercial viability. The path forward rewards integrated thinking and disciplined execution across the entire value chain.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in off-the-shelf allogeneic CAR-T therapies using gene editing to reduce graft-versus-host risk
  • 5.2. Development of armored CAR-T cells secreting cytokines to enhance solid tumor microenvironment infiltration
  • 5.3. Incorporation of CRISPR-mediated multiplex gene editing to improve T cell persistence and safety profiles
  • 5.4. Integration of automated closed-system manufacturing platforms to scale up CAR-T production and reduce costs
  • 5.5. Combination strategies pairing engineered T cells with immune checkpoint inhibitors for synergistic antitumor response
  • 5.6. Emergence of bispecific CAR-T constructs targeting dual antigens to prevent tumor antigen escape in treatment-resistant cancers
  • 5.7. Regulatory pathways evolving for engineered T cell therapies with emphasis on harmonized global approval processes
  • 5.8. Adoption of artificial intelligence algorithms to design personalized neoantigen-targeted T cell receptors
  • 5.9. Launch of induced pluripotent stem cell-derived CAR-T products aiming to standardize cell therapy supply chains
  • 5.10. Implementation of real-time in vivo CAR-T cell tracking using molecular imaging for safety and efficacy monitoring
  • 5.11. Market access initiatives focusing on innovative reimbursement models and outcomes-based contracting for CAR-T therapies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Engineered T Cells Market, by Therapy Type

  • 8.1. CAR T
  • 8.2. TCR T

9. Engineered T Cells Market, by Cell Source

  • 9.1. Allogeneic
  • 9.2. Autologous

10. Engineered T Cells Market, by Phase

  • 10.1. Phase I
  • 10.2. Phase Ii
  • 10.3. Phase Iii
  • 10.4. Preclinical

11. Engineered T Cells Market, by Application

  • 11.1. Autoimmune Diseases
    • 11.1.1. Lupus
    • 11.1.2. Rheumatoid Arthritis
  • 11.2. Infectious Diseases
  • 11.3. Oncology
    • 11.3.1. Acute Lymphoblastic Leukemia
    • 11.3.2. Non Hodgkin Lymphoma
    • 11.3.3. Solid Tumor
      • 11.3.3.1. Glioblastoma
      • 11.3.3.2. Lung Cancer

12. Engineered T Cells Market, by End User

  • 12.1. Hospital
  • 12.2. Research Institutes
  • 12.3. Specialty Clinics

13. Engineered T Cells Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Engineered T Cells Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Engineered T Cells Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Novartis AG
    • 16.3.2. Gilead Sciences, Inc.
    • 16.3.3. Bristol-Myers Squibb Company
    • 16.3.4. Johnson & Johnson
    • 16.3.5. Legend Biotech Corporation
    • 16.3.6. Allogene Therapeutics, Inc.
    • 16.3.7. Adaptimmune Therapeutics plc
    • 16.3.8. Poseida Therapeutics, Inc.
    • 16.3.9. Celyad Oncology SA
    • 16.3.10. Sangamo Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENGINEERED T CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ENGINEERED T CELLS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ENGINEERED T CELLS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ENGINEERED T CELLS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ENGINEERED T CELLS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ENGINEERED T CELLS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY CAR T, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY CAR T, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY CAR T, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY CAR T, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY CAR T, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY CAR T, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY TCR T, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY TCR T, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY TCR T, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY TCR T, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY TCR T, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY TCR T, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ALLOGENEIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ALLOGENEIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ALLOGENEIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ALLOGENEIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ALLOGENEIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE I, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE I, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE I, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE I, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE I, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE II, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE II, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE II, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE II, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE II, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE III, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE III, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE III, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE III, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE III, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PRECLINICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PRECLINICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PRECLINICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY LUPUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY LUPUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY LUPUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY LUPUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY LUPUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY LUPUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY NON HODGKIN LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY NON HODGKIN LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY NON HODGKIN LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY NON HODGKIN LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY NON HODGKIN LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY NON HODGKIN LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY GLIOBLASTOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY GLIOBLASTOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY GLIOBLASTOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY GLIOBLASTOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE ENGINEERED T CELLS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2025-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 271. AFRICA ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2024 (USD MILLION)
  • TABLE 272. AFRICA ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2025-2032 (USD MILLION)
  • TABLE 273. AFRICA ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. AFRICA ENGINEERED T CELLS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2024 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2025-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. ASEAN ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. ASEAN ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. ASEAN ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. ASEAN ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. ASEAN ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 300. ASEAN ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 301. ASEAN ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
  • TABLE 302. ASEAN ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2025-2032 (USD MILLION)
  • TABLE 303. ASEAN ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 304. ASEAN ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 305. ASEAN ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 306. ASEAN ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 307. ASEAN ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 308. ASEAN ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 309. ASEAN ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2024 (USD MILLION)
  • TABLE 310. ASEAN ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2025-2032 (USD MILLION)
  • TABLE 311. ASEAN ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 312. ASEAN ENGINEERED T CELLS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 313. GCC ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 314. GCC ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 315. GCC ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 316. GCC ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 317. GCC ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 318. GCC ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 319. GCC ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
  • TABLE 320. GCC ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2025-2032 (USD MILLION)
  • TABLE 321. GCC ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 322. GCC ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 323. GCC ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 324. GCC ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 325. GCC ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 326. GCC ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 327. GCC ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2024 (USD MILLION)
  • TABLE 328. GCC ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2025-2032 (USD MILLION)
  • TABLE 329. GCC ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 330. GCC ENGINEERED T CELLS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 331. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 332. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 333. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 334. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 335. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 336. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 337. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
  • TABLE 338. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2025-2032 (USD MILLION)
  • TABLE 339. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 340. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 341. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2